FIELD study: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}}; {{AE}} {{Rim}} ==Official Title== Fenofibrate Intervention and Event Lowering in Diabetes ==Objective== The objective of thi...") |
Rim Halaby (talk | contribs) |
||
| Line 32: | Line 32: | ||
|- | |- | ||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | | Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | ||
|- | |- | ||
| '''Condition'''||Diabetes Mellitus type 2 | | '''Condition'''||Diabetes Mellitus type 2 | ||
Revision as of 23:37, 18 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
FIELD study On the Web |
|
American Roentgen Ray Society Images of FIELD study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Official Title
Fenofibrate Intervention and Event Lowering in Diabetes
Objective
The objective of this study is to determine the risk of fatal coronary heart disease among subjects with type 2 diabetes who are administered fenofibrate.
Timeline
| Timeline | |
| Start Date | 01/01/1998 |
| End Date | 31/12/2005 |
| Status | Completed |
Study Description
| Study Description | |
| Study Type | Randomized |
| Study Details | |
| Condition | Diabetes Mellitus type 2 |
| Intervention | Fenofibrate Placebo |
| Population Size | 9,795 |